ECOG-ACRIN Cancer Research Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ECOG-ACRIN Cancer Research Group sits in the top decile of US sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count).
ECOG-ACRIN Cancer Research Group: 75 sponsored US clinical trials, 12 recruiting.
ECOG-ACRIN Cancer Research Group sponsors 75 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 16 completed. 23 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Invasive Breast Carcinoma, with 3 trials.
Top-decile sponsor footprint
ECOG-ACRIN Cancer Research Group ranks in the top decile of sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 26 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (61.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
75 total, page 1 of 2
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
NCT06319027
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT03493425
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05721755
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT05710328
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
NCT04484818
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406
Cancer and Blood Pressure Management, CARISMA Study
NCT04467021
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866
Comparing Two Methods to Follow Patients With Pancreatic Cysts
NCT04239573
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT04266249
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT04115631
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
NCT04001829
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT03697148
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
NCT03504644
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
NCT03516942
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
NCT03419234
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
NCT03233191
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
NCT03253848
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333
Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
NCT02933489
Reproductive Health Program in Patients With Cancer
NCT01806129
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
NCT02595424
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
NCT02352883
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
NCT01898494
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01863550
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT01824875
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
NCT01824836
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
NCT00003641
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
NCT04221438
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 33 |
| Phase 3 | 23 |
Therapeutic Areas
What is open in the ECOG-ACRIN Cancer Research Group pipeline
12 recruiting of 75 indexed (16% open); 16 completed (21%).
Phase mix: 23 late (III/IV) vs 35 early (I/II) (early-phase heavy).
Top condition: Invasive Breast Carcinoma (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ECOG-ACRIN Cancer Research Group: open-pipeline peers nationwide
Peers matched on 75 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
ECOG-ACRIN Cancer Research Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 75 trials (± recruiting share)
- C. R. Bard · 75 trials · 5% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
- Ionis Pharmaceuticals · 76 trials · 12% recruiting
Sponsors near 16% open enrollment (± trial volume)
- George Mason University · 16% recruiting · 25 trials
- University of Arizona · 16% recruiting · 349 trials
- University of California, San Francisco · 16% recruiting · 1,713 trials
- University of Oregon · 16% recruiting · 63 trials
Related
What to do with this ECOG-ACRIN Cancer Research Group page
75 registered trials is a research-attention snapshot, not an endorsement of ECOG-ACRIN Cancer Research Group or any single study.
- 12 of ECOG-ACRIN Cancer Research Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Invasive Breast Carcinoma is the condition ECOG-ACRIN Cancer Research Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Invasive Breast Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ECOG-ACRIN Cancer Research Group pipeline card: 75 registered trials from official public datasets.Report a data error.